Journal of Cell Science & Therapy
Open Access

The Significance of Regeneration and Reposition of Islets

Lans Moller^{* *}Correspondence: Lans Moller, Department of Pharmacology, University of Namibia, Windhoek, Namibia, Email:

Author info »

Description

Research investigations focused on the biology, regeneration, and transplantation of islets continue to give light on the aetiology of various forms of diabetes and provide new impetus for the hunt for a "cure." Diabetes is caused by an insufficient number of insulin-producing beta cells in the pancreas. While type 1 diabetes is marked by the entire loss of beta cells as a result of an autoimmune attack, type 2 diabetes is marked by a relative deficit of beta cells as a result of lower insulin resistance compensation. Restoring beta-cell mass and reversing diabetes can be accomplished in one of two ways: endogenous beta-cell regeneration or exogenous beta-cell transplantation; current advances in science and technology have aided progress in both. While efforts to increase mature beta-cells in vitro have had mixed results, regeneration of beta-cells from embryonic and adult stem cells, also known as pancreatic progenitor cells, has shown promise. Understanding the role of beta-cell-specific transcription factors in trans-differentiation to the beta-cell phenotype is essential for future research.

Pharmacological techniques that use growth factors, hormones, and small compounds to increase beta-cell proliferation and function have also been demonstrated. In the second strategy, isolated islets from cadaveric donor pancreas have proven to be a quick and effective method for replacing exhausted beta-cells in type 1 diabetes patients, allowing them to achieve exogenous insulin independence. Islet transplant recipients, on the other hand, require immunosuppression to protect the transplanted beta-cell mass, which is known to be beta-cell toxic under current regimens. This constraint has resulted in poor long-term function of the transplanted islets, as well as a disillusioned medical community dedicated to providing patients with a longterm solution.

The dearth of acceptable donor pancreases is clearly one of the key obstacles to continued success in islet transplantation. This problem is exacerbated by the fact that allotransplanted islets have a low long-term survival rate. Gene therapy provides a potent tool for engineering islet grafts to become resistant to inflammation-induced apoptosis and to create immunosuppressive compounds to reduce T-cell response. In addition, the use of iPSC-derived pancreatic beta-like cells to produce patient-specific, autologous beta-cell replacement therapy is described.

Other recent studies have found that effective induction immunosuppression and inflammation control can improve the long-term performance of allogeneic islet transplants. Controlling the immune response to islet transplants, both autologous and allogeneic, will be necessary to improve longterm success. To improve the longevity of both solid organ and cell transplants, transplant immunologists are pursuing the donor-specific tolerance. Because the present immunosuppressive regimen employed in islet transplantation may be hazardous to beta-cells, the discovery of tolerance inducing therapies is critical for the future of islet transplantation. Better outcomes will be achieved with a treatment regimen that selectively targets donor-reactive T cells while growing populations of regulatory T cells. Inherently tolerogenic cells like hepatic stellate cells, sertoli cells, and mesenchymal stem cells will be studied further to aid in the development of medicines.

Conclusion

Islet cell transplantation has the potential to cure type 1 diabetes, but it is complicated by a lack of donor tissue and the negative effects of current immunosuppressive medicines. To improve the efficiency and safety of this treatment, alternative sources of insulin-producing cells and islet-friendly immunosuppression are necessary. To compensate for diabetic patients' diminished beta-cell function and insulin resistance, beta-cells can be transdifferentiated from progenitors or another heterologous (non-beta-cell) source. Fortunately, recent advances in our understanding of islet cell biology and beta-cell regeneration have brought the field of islet cell transplantation one step closer to our objective of discovering a diabetes cure.